The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a study which indirectly compared anemia outcomes and safety data for momelotinib and pacritinib in patients with myelofibrosis (MF). This study compared data from a variety of studies, and found that momelotinib displayed superior efficacy in terms of anemia improvement and incidence of gastrointestinal adverse events (AEs). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
